BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 34162861)

  • 1. A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry.
    Chen Y; Lear TB; Evankovich JW; Larsen MB; Lin B; Alfaras I; Kennerdell JR; Salminen L; Camarco DP; Lockwood KC; Tuncer F; Liu J; Myerburg MM; McDyer JF; Liu Y; Finkel T; Chen BB
    Nat Commun; 2021 Jun; 12(1):3907. PubMed ID: 34162861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry.
    Chen Y; Lear TB; Evankovich JW; Larsen MB; Lin B; Alfaras I; Kennerdell JR; Salminen L; Camarco DP; Lockwood KC; Liu J; Myerburg MM; McDyer JF; Liu Y; Finkel T; Chen BB
    Res Sq; 2020 Aug; ():. PubMed ID: 32818215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    Muralidar S; Gopal G; Visaga Ambi S
    J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Huang ST; Chen Y; Chang WC; Chen HF; Lai HC; Lin YC; Wang WJ; Wang YC; Yang CS; Wang SC; Hung MC
    Viruses; 2021 May; 13(5):. PubMed ID: 34063247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections.
    Sato T; Ueha R; Goto T; Yamauchi A; Kondo K; Yamasoba T
    Laryngoscope; 2021 Mar; 131(3):E932-E939. PubMed ID: 32940922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein.
    Sagar S; Rathinavel AK; Lutz WE; Struble LR; Khurana S; Schnaubelt AT; Mishra NK; Guda C; Palermo NY; Broadhurst MJ; Hoffmann T; Bayles KW; Reid SPM; Borgstahl GEO; Radhakrishnan P
    Clin Transl Med; 2021 Feb; 11(2):e281. PubMed ID: 33635001
    [No Abstract]   [Full Text] [Related]  

  • 13. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
    Choi Y; Shin B; Kang K; Park S; Beck BR
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells.
    Leach DA; Mohr A; Giotis ES; Cil E; Isac AM; Yates LL; Barclay WS; Zwacka RM; Bevan CL; Brooke GN
    Nat Commun; 2021 Jul; 12(1):4068. PubMed ID: 34210968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
    Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.